The positive is that NPAT guidance is unchanged and 2H21 is expected to deliver ~2.5 times 1H21 NPAT
The negative it calling professional services from ongoing client demand is 'attached recurring revenue'......it declined over the last two 6 month reporting periods so is that really that reliable to term recurring.....I'm sure there is a better way to express this, because it looks like an own goal to class this as 'recurring revenue' when it has declined for a SaaS company. The other point of concern is that R&D capitalised increased significantly in 1H21......R&D in itself is not bad, but was this capitalised to make the 1H21 results look better than reported.....perhaps legit, and perhaps they redeployed project staff into R&D but interesting to see how this looks in 2H21.
Anyway, FY 2021 NPAT of 32-35m means EPS of 13-14c and a PE of 21-23 on FY2021 earnings...nNot necessarily expensive, but perhaps appropriate given the growth reflected in the last 9 months.
2H21 project fees will highlight a turnaround I think
BVS Price at posting:
$3.05 Sentiment: None Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)